| Literature DB >> 32930881 |
Uwe Ernsberger1, Thomas Deller1, Hermann Rohrer2.
Abstract
Selective sympathetic and parasympathetic pathways that act on target organs represent the terminal actors in the neurobiology of homeostasis and often become compromised during a range of neurodegenerative and traumatic disorders. Here, we delineate several neurotransmitter and neuromodulator phenotypes found in diverse parasympathetic and sympathetic ganglia in humans and rodent species. The comparative approach reveals evolutionarily conserved and non-conserved phenotypic marker constellations. A developmental analysis examining the acquisition of selected neurotransmitter properties has provided a detailed, but still incomplete, understanding of the origins of a set of noradrenergic and cholinergic sympathetic neuron populations, found in the cervical and trunk region. A corresponding analysis examining cholinergic and nitrergic parasympathetic neurons in the head, and a range of pelvic neuron populations, with noradrenergic, cholinergic, nitrergic, and mixed transmitter phenotypes, remains open. Of particular interest are the molecular mechanisms and nuclear processes that are responsible for the correlated expression of the various genes required to achieve the noradrenergic phenotype, the segregation of cholinergic locus gene expression, and the regulation of genes that are necessary to generate a nitrergic phenotype. Unraveling the neuron population-specific expression of adhesion molecules, which are involved in axonal outgrowth, pathway selection, and synaptic organization, will advance the study of target-selective autonomic pathway generation.Entities:
Keywords: Neuron; Neurotransmitter; Parasympathetic; Pelvic; Sympathetic
Mesh:
Year: 2020 PMID: 32930881 PMCID: PMC7584561 DOI: 10.1007/s00441-020-03279-6
Source DB: PubMed Journal: Cell Tissue Res ISSN: 0302-766X Impact factor: 5.249
The expression of cholinergic, nitrergic, and noradrenergic transmitter synthesis enzymes in rat and human cranial parasympathetic ganglia
| Cholinergic | CIL | OG | SPG | PG | ||
| ChAT | Rat | Virt. all | (Landis et al. | |||
| All | All | < 100% | (Leblanc et al. | |||
| Nitrergic | CIL | OG | SPG | SMG | ||
| NOS | Rat | majority 40%+++ 30%+ | (Warn et al. | |||
| 70 to 80% | (Nozaki et al. | |||||
| Human | 75 to 80% | 75 to 80% | (Uddman et al. | |||
| Noradrenergic | CIL | OG | SPG | SMG | ||
| CA | rat | no | no | no | (Leblanc et al. | |
| TH | > 30% | < 1% | < 1% | |||
| TH | 1.8% | (Leblanc and Landis | ||||
| TH | 25–40% | No | (Landis et al. | |||
| TH/DBH | 3% | |||||
| TH | Human | 23% | (Kirch et al. | |||
| DBH | no |
The proportion of neurones expressing the cholinergic marker enzyme ChAT, the nitrergic marker enzyme NOS, and the noradrenergic marker enzymes TH and DBH as detected by immunohistochemistry in rat and human cranial ganglia are provided
CIL, ciliary ganglion; OG, otic ganglion; SPG, sphenopalatine ganglion; SMG, submandibular ganglion; TH/DBH, percentage of TH and DBH double-positive cells
The expression of noradrenergic markers in adult human sympathetic ganglia
| SCG | MCG | STG | Thoracic | Sacral | ||
|---|---|---|---|---|---|---|
| TH | 83.8% | 59.3% | 70.4% | (Kokubun et al. | ||
| 75% | (Schalling et al. | |||||
| > 75% | (Tajti et al. | |||||
| 90% | (Takenaka et al. | |||||
| Virt. all | (Kirch et al. | |||||
| Rich | (Baffi et al. | |||||
| DBH | 91% | 92.1% | 94.2% | (Kokubun et al. | ||
| 75% | (Schalling et al. | |||||
| Virt. all | (Kirch et al. | |||||
| Similar to TH | (Baffi et al. |
The proportion of neurons immunopositive for the noradrenergic marker enzymes TH and DBH for different human cervical and paravertebral sympathetic ganglia are provided
SCG, superior cervical ganglion; MCG, middle cervical ganglion; STG, stellate ganglion. Virt. all indicates that virtually all neurons are positive; rich indicates a rich supply of positive neurons; similar TH indicates that the number of DBH and TH-positive cells are similar as expected for cells co-expressing the noradrenergic marker enzymes
Neuropeptide expression in sympathetic ganglia of adult guinea pigs
| SCG | Thoracic | Lumbar | CEG/SMG | IMG | ||
|---|---|---|---|---|---|---|
| VIP | 11% | 13% | (Gibbins | |||
| < 1% | (Lindh et al. | |||||
| 1 to 2% | (Parr and Sharkey | |||||
| NPY | 57% | 73% | (Gibbins | |||
| 65% | (Lindh et al. | |||||
| App. 20% | (Parr and Sharkey | |||||
| App. 22% | (Sann et al. | |||||
| SOM | Single | Significant | (Lundberg et al. | |||
| 25% | (Lindh et al. | |||||
| Single | 59% in AI, 25% in PS | 62.5% | (Hokfelt et al. | |||
| App. 80% | (Sann et al. | |||||
| App. 80% | (Parr and Sharkey |
The proportion of neurones immunopositive for the neuropeptides VIP, NPY and SOM in different sympathetic ganglia are provided
SCG, superior cervical ganglion; CEG/SMG, celiac ganglion/superior mesenteric ganglia; IMG, inferior mesenteric ganglion; AI, anterior–inferior part of the ganglion complex; PS, posterior-superior part of the ganglion complex; “single” and “significant” refer to only single cells as compared with significant numbers of cells in the ganglion. “App.” indicates approximate estimates
Development of VIP and NPY expression in the rat sympathetic ganglia
| Onset | % at onset | P0 | P10 | P60 | ||
|---|---|---|---|---|---|---|
| VIP | ||||||
| SCG | E14.5 | App. 30% | 2% | (Tyrrell and Landis | ||
| STG | 5% | 6% | 3% | (Masliukov and Timmermans | ||
| NPY | ||||||
| SCG, STG | E12.5 | Almost all | 55% | (Tyrrell and Landis | ||
| SCG | 50% | 57% | 65% | (Masliukov et al. | ||
| STG | 40% | 45% | 55% | (Masliukov and Timmermans | ||
| CEG | 65% | 62% | 80% | (Masliukov et al. | ||
The proportions of neurons that are immunopositive for the neuropeptides VIP and NPY in rat sympathetic ganglia at different developmental stages are provided. The expression onset is provided with the embryonic day (E) of first marker detection and the proportion (%) of positive cells on the day of expression onset. The proportion of positive cells is also provided for postnatal (P) day 0 to 60 animals
SCG, superior cervical ganglion; SCG, stellate ganglion; CEG, celiac ganglion
Expression of selected transcription factors in mouse thoracic sympathetic neurons
| NA1 | NA2 | NA3 | NA4 | NA5 | Ach1 | Ach2 | |
|---|---|---|---|---|---|---|---|
| Phox2b | 5.3 | 7.59 | 5.97 | 5.89 | 4.09 | 5.25 | 3.38 |
| Phox2a | 6.8 | 5.85 | 7.61 | 6.06 | 5.39 | 6.12 | 3.38 |
| Ascl1 | 0.1 | 0 | 0.08 | 0 | 0 | 0 | 0 |
| Hand1 | 3.3 | 4.13 | 3.48 | 2.33 | 3.26 | 2 | 1.5 |
| Hand2 | 7.6 | 11.87 | 11.54 | 11.78 | 11.87 | 8 | 7.75 |
| Gata2 | 5.8 | 7.41 | 6.64 | 5.72 | 5.48 | 2.5 | 1.38 |
| Gata3 | 2.8 | 3.54 | 3.35 | 5.06 | 4.35 | 3.12 | 1.88 |
| Hmx1 | 1.6 | 1.33 | 2.17 | 1.22 | 1.17 | 0.25 | 0 |
| Hmx 2/3 | ND | ND | ND | ND | ND | ND | ND |
| Insm1 | 0.1 | 0.05 | 0.17 | 0 | 0.04 | 0 | 0 |
| Insm2 | 1.5 | 2.05 | 2.01 | 2.56 | 1.48 | 0 | 0 |
The numbers given are mean number of transcripts per cell in the indicated noradrenergic (NA 1–5) and cholinergic (Ach1 and 2) sympathetic neuron subpopulations as analyzed by single cell RNA sequencing (Furlan et al. 2016). Whereas no major differences are observed for Phox2 transcript levels, Hand 1 and 2 transcripts in noradrenergic neurons in general exceed those in cholinergic neurons in number. Similar differences are observed for Gata 2 and 3. Whereas HMX1 is detected at least 5-fold higher levels in noradrenergic than cholinergic neurons, HMX 2 and 3 transcripts are not found in any sympathetic neuron population, neither noradrenergic nor cholinergic. The most striking difference between noradrenergic and cholinergic neurons is observed for Insm2. Data derived from Furlan et al. (2016), supplementary table nn 4376-s4
Fig. 1Schematic illustration of the gene regulatory network controlling sympathetic neuron differentiation. Arrows indicate target gene expression, proliferation, or survival affected by transcription factor knockout. Initial development is only affected by Phox2b, Hand2, and Gata2/3. References for individual TFs: Phox2b (Pattyn et al. 1999); Ascl1 (Pattyn et al. 2006); Hand2 (Lucas et al. 2006; Hendershot et al. 2008; Schmidt et al. 2009); Gata2/3 (Lim et al. 2000; Tsarovina et al. 2004; Tsarovina et al. 2010); Insm1 (Wildner et al. 2008); Sox4/Sox11 (Potzner et al. 2010); Isl1 (Huber et al. 2013); Hmx1 (Furlan et al. 2013); Tlx3 (Furlan et al. 2013; Huang et al. 2013)
Expression of the neurotransmitter synthesizing enzymes TH, DBH, CHAT, and NOS in male and female rodent pelvic neurons
| (A) Male rodent pelvic ganglia | ||||||
| Male MPG/APG | TH+ | TH+/ChAT+ | TH−/ChAT− | ChAT+ | NOS+ | |
| Rat MPG | ≈ 33% | 0.5% | 1 to 2% | 2/3 | (Keast et al. | |
| 26%TH+/NPY+ | (Keast 1995) | |||||
| GP APG | 22% | (Song et al. | ||||
| GP APG | Minority, all NOS−, few DBH− | No | Many, all NOS+ | Majority, many CHAT+, some DBH+ | (Elfvin et al. | |
| Mus MPG | 34/31% | < 1% | < 5% | (Wanigasekara et al. | ||
| 21% | 47.1% | (Yan and Keast | ||||
| (B) Female rodent pelvic ganglia | ||||||
| Female | TH | ChAT | NOS | |||
| Rat PCG | 9% | (Houdeau et al. | ||||
| Rat AG | 20.4% | |||||
| Rat HP | 12.7% | |||||
| Rat MPG | Minority, all ChAT− | Majority, all TH− | Many, all ChAT+ | (Persson et al. | ||
| GP PCG | TH | DDC | DBH | |||
6–9% all DBH+ | ≈ 10% TH/DBH+ | 57 to 73%, many TH− | (Morris and Gibbins | |||
MPG, major pelvic ganglion; APG, male anterior pelvic ganglion; PCG, female paracervical ganglia; AG, female accessory ganglia; HP, female hypogastric plexus
Proportions of immunopositive cells for the indicated neurotransmitter phenotype markers in rat, guinea pig (GP), and mouse (Mus) pelvic ganglia. Mouse data are obtained for two different mouse strains (see text) and, when the mean numbers between the two strains differ in a notable way, are separated by /. Marker A+ indicates the proportion of cells positive for this marker. Marker A+/marker B+ indicates the proportion of marker B-positive cells double-positive for both markers. Marker A−/marker B− indicates the proportion of cells negative for both markers. The labels “all,” “many,” and “some” in combination with “B−/+” in a column A indicate the proportion of cells positive for the marker A (indicated at the top of the column) that are negative or positive for the marker B. The labels “no,” “minority,” “many,” and “majority” indicate the proportion of cells positive for the respective marker indicated at the top of the column
Expression of the neuropeptides VIP and NPY in pelvic ganglia of different rodent species, strains, and sexes and the correlation with neurotransmitter-synthesizing enzymes
| (A) Proportions of immunopositive cells for the indicated neuropeptides in rat, guinea pig (GP), and mouse (Mus) pelvic ganglia are provided. Data for mouse are obtained for two different mouse strains (QS, C57). Numbers are given for VIP and NPY-positive cells as well as for VIP/NPY double-positive cells (VIP+NPY+) | ||||||
| Ganglion | VIP+ | NPY+ | VIP+NPY+ | |||
| Male | ||||||
| Rat | MPG | 44% | 66% | 3.7% | (Keast | |
| Mus QS | MPG | 55% | 93% | 50% | (Wanigasekara et al. | |
| Mus C57 | MPG | 43% | 67% | 24% | ||
| Female | ||||||
| Rat | PCG | 46% | 84% | some | (Houdeau et al. | |
| AG | 91% | 89% | 81% | |||
| HP | 89% | 94% | ||||
| GP | PCG | 62 to 65% | 72 to 84% | 61% | (Morris and Gibbins | |
| PCG | 60% | (Anderson et al. | ||||
| (B) The proportion of VIP and NPY-positive cells among ChAT-positive and -negative as well as NOS-positive cells is provided. The terms “all,” “almost all,” “many,” and “frequently” indicate the size of the respective subpopulation unless given as precise percentages | ||||||
| Ganglion | ChAT+/VIP | ChAT−/VIP | NOS+/VIP | NOS+/NPY | ||
| Male rat | MPG | Almost all | 3.5% | (Keast | ||
| Male GP | APG | Many | Frequently | (Elfvin et al. | ||
| Fem. rat | MPG | All | (Persson et al. | |||
| almost all | (Alm et al. | |||||
| fem. GP | PCG | 97% | 97% | (Anderson et al. | ||
MPG, male major pelvic ganglion; PCG, female paracervical ganglion; AG, female accessories ganglia; HP, female hypogastric plexus
MPG, male or female major pelvic ganglion; APG, male anterior pelvic ganglion; PCG, female paracervical ganglia
Expression of neurotransmitter-synthesizing enzymes and neuropeptides in the neurones of the human pelvic plexus
| (A) The proportions of cells immunopositive for TH, VAChT, both markers (TH/VAChT), or NOS. Numbers are listed according to age for adults (39 to 85 years) as well as neonates, infants, and children (2 months to 7 years) | |||||||
| Donor age | Site | TH | TH/VAChT | VAChT | NOS | ||
| 72–85 years | PP | 58% | (Takenaka et al. | ||||
| Mean 79 years | PP | > 50% | (Imai et al. | ||||
| 64–82 years | PP | > than TH | (Muraoka et al. | ||||
| 39–77 years | PP DD SV | Variable | (Grozdanovic and Goessl | ||||
| 7 weeks–6 years | PP, male | 8% | (Dixon et al. | ||||
| 6 months–7 years | PP, male | 40% | 65% | (Dixon et al. | |||
| 2 to 12 months | AB | 45% | (Jen et al. | ||||
| AP | 67% | ||||||
| (B) The proportion of TH-positive, TH-negative, and VAChT-positive cells (co)expressing NOS in human pelvic plexus ganglia of infants and children | |||||||
| NOS/TH+ | NOS/TH − | NOS/VAChT+ | |||||
| AB | 61% | 77% | (Jen et al. | ||||
| AP | 38% | 59% | |||||
| PP | 65% | (Dixon et al. | |||||
| (C) The expression of NPY and VIP in TH-positive and -negative as well as VAChT-positive human pelvic plexus neurones in infants and children | |||||||
| NPY | NPY/VAChT | VIP/TH+ | VIP/TH− | NPY/TH+ | NPY/TH− | ||
| AB | 64% | 83% | 66% | 92% | (Jen et al. | ||
| AP | 42% | 82% | 62% | 65% | |||
| PP | 85% | Almost all | (Dixon et al. | ||||
PP, pelvic plexus; PP DD SV, pelvic plexus ganglion cell clusters near ductus deferens and seminal vesicles; AB, extramural ganglia adjacent to the bladder; AP, extramural ganglia adjacent to the prostate
> than TH: the proportion of NOS-positive cells exceeds that of TH-positive cells; variable: highly divergent proportions of NOS-positive cells
AB, adjacent to bladder; AP, adjacent to prostate gland; PP, pelvic plexus
The majority of TH-positive as well as TH-negative neurons in infants and children pelvic plexus ganglia express NPY and VIP. “Almost all” VAChT-positive neurons express NPY. The situation in adults and the comparison between males and females could not be retrieved from PubMed
Expression of neurotransmitter-synthesizing enzymes and neuropeptides in intramural ganglia of human bladder
| (A) The proportions of neurones immunopositive for the neurotransmitter phenotype markers NOS, TH, DBH, and VAChT. Numbers are provided for adult tissue obtained from cancer patients and neonates, infants, and children (at 2 months to 6 years of age) dying from sudden child’s death (CD) or accidental trauma (AT) | ||||||
| Age | Death | % NOS | NOS/TH+ | NOS/TH− | NOS/VAChT | |
| Adult | Cancer | 86% | (Smet et al. | |||
| 7 weeks–6 years | CD, AT | 40% | (Dixon et al. | |||
| 2 months–3 years | 58% | 45% | (Dixon et al. | |||
| (B) The proportion of neurons immunopositive for noradrenergic and cholinergic markers in intramural ganglia of adult humans as compared with neonates and children | ||||||
| Age | Death | TH | TH+DBH+ | TH+VAChT+ | VAChT | |
| Adult | Cancer | 14% | (Smet et al. | |||
| 7 weeks–6 years | CD, AT | 75% | (Dixon et al. | |||
| 7 weeks–6 years | CD, AT | 25% no VAChT | 50% | 25% no TH | (Dixon et al. | |
| 2 months–3 years | CD, AT | 40% | (Dixon et al. | |||
| (C) The proportion of neurons immunopositive for the neuropeptides VIP, NPY, CGRP, SOM, and GAL | ||||||
| Age | VIP | NPY | CGRP | SOM | GAL | |
| Adult | 77% | 58% | 0% | 0% | 65% | (Smet et al. |
| 2 months–3 years | 45% TH− | 90% TH− | 65% TH− | 90% TH− | (Dixon et al. | |
| 40% TH+ | 70% TH+ | 54% TH+ | 73% TH+ | |||
%: The overall proportion of positive cells in intramural ganglia. NOS/marker B−/+ indicates the proportion of NOS-positive cells among marker B-negative or positive cells. In infants and children, approximately half of TH-negative as well as -positive express NOS. The corresponding numbers for adults are not determined
Whereas 40% of the cells express TH in neonates and children, their proportion drops to 14% in adults. Coexpression of TH is observed with DBH or VAChT
Massive changes are observed in neuropeptide expression patterns between infants and adults. The proportion of VIP-positive cells increases and of NPY-positive cells decreases with age. Particularly striking appear the loss in CGRP and SOM expression
Fig. 2Transcription factors in autonomic neuron differentiation. Transcription factors detected during embryonic differentiation of autonomic postganglionic neurons in mice are shown for cranial, paravertebral, and pelvic ganglia. Their function, as far as they are characterized, are indicated and discussed in the text. The basic helix-loop-helix protein Hand 1 and the zinc finger protein Gata 3 are selective markers for sympathetic and pelvic neuron development. The H6 family homeobox protein homologues HMX 2 and 3 are selective markers for cranial postganglionic neurons and distinguish parasympathetic from the sympathetic and pelvic neuron lineages. a(Pattyn et al. 1999); b(Morin et al. 1997; Pattyn et al. 1997); c(Coppola et al. 2005); d(Hirsch et al. 1998); e(Pattyn et al. 2006); f(Espinosa-Medina et al. 2016); g(George et al. 1994; Lim et al. 2000; Tsarovina et al. 2004; Moriguchi et al. 2006; Tsarovina et al. 2010; Espinosa-Medina et al. 2016); h(Espinosa-Medina et al. 2016); i(Espinosa-Medina et al. 2016); j(Doxakis et al. 2008; Espinosa-Medina et al. 2016; Firulli et al. 2017), k(Espinosa-Medina et al. 2016); l(Müller and Rohrer 2002; VanDusen et al. 2014; Stanzel et al. 2016); m(Howard et al. 1999; Howard et al. 2000; Lucas et al. 2006; Morikawa et al. 2007; Hendershot et al. 2008; Schmidt et al. 2009; Vincentz et al. 2012); n(Wang et al. 2000); o(Yoshiura et al. 1998; Furlan et al. 2013); p(Wiese et al. 2012); q(Espinosa-Medina et al. 2016)
Fig. 3Presence of the classical neurotransmitters noradrenaline and acetylcholine, the small molecule neuromodulator nitric oxide and the neuropeptides NPY and VIP in cranial autonomic, sympathetic, and pelvic ganglia. The length of the bars indicate the proportion of neurons positive for the respective marker. The horizontal position indicates presence in cranial, sympathetic, and pelvic ganglia as well as their co-expression with other markers. Both proportion and co-expression are detailed in the manuscript text and tables. Data shown are mainly from rat. As for rat pelvic ganglia, quantification of the proportion of DBH-positive cells is not available; data from the guinea pig are shown
Fig. 4The expression of cell adhesion molecules, axonal outgrowth and synaptic organizer proteins in noradrenergic and cholinergic classes of mouse sympathetic neurons. The mean number of transcripts for the indicated genes are shown as determined by single cell RNA sequencing for the indicated populations of noradrenergic (NA1–5) and cholinergic (Ach1, 2) neurons from mouse thoracic sympathetic ganglia as provided by Furlan et al. (2016; supplementary table nn 4376-S4)